Pierre Kyme - 14 Mar 2026 Form 4 Insider Report for Armata Pharmaceuticals, Inc. (ARMP)

Reporting relationship: Chief Business Officer
Issuer ticker: ARMP
Reported as of: 14 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Mar 2026, 19:48:27 UTC
Prior SEC filing: 11 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Pierre Kyme

Key filing fact

Pierre Kyme filed Form 4 for Armata Pharmaceuticals, Inc. (ARMP) on 17 Mar 2026.

Key facts

This page summarizes Pierre Kyme's Form 4 filing for Armata Pharmaceuticals, Inc. (ARMP).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 17 Mar 2026, 19:48.

Change

Previous filing in this sequence was filed on 11 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002028892 Primary reporting owner

Kyme Pierre

Relationship: Chief Business Officer
Address: 5005 MCCONNELL AVENUE, LOS ANGELES
Signature: /s/ Pierre Kyme
Signature date: 17 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ARMP transaction

Common Stock

Tax liability

Transaction value
Shares: -1,030
Change %: -9.8%
Price: $10.54^*
Shares after: 9,461
Date: 14 Mar 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents shares that have been withheld by the Company to satisfy its income tax and withholding remittance obligations in connection with the net settlement of restricted stock units.